Panwar Bhupesh, Jenny Nancy S, Howard Virginia J, Wadley Virginia G, Muntner Paul, Kissela Brett M, Judd Suzanne E, Gutiérrez Orlando M
From the Departments of Medicine (B.P., V.G.W., P.M., O.M.G.), Epidemiology (V.J.H., P.M., O.M.G.), and Biostatistics (S.E.J.), University of Alabama at Birmingham; Department of Pathology, University of Vermont, Burlington (N.S.J.); and Department of Neurology, University of Cincinnati, OH (B.M.K.).
Stroke. 2015 Feb;46(2):322-8. doi: 10.1161/STROKEAHA.114.007489. Epub 2015 Jan 6.
Fibroblast growth factor 23 (FGF23) is a hormone that regulates phosphorus and vitamin D metabolism. Elevated FGF23 concentrations are associated with excess risk of cardiovascular disease. Associations of FGF23 with stroke outcomes are less clear.
Using a case-cohort study design, we examined the association of baseline plasma FGF23 concentrations with incident stroke in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) study, a cohort of black and white adults aged ≥45 years. FGF23 was measured in 615 participants who developed incident stroke (cases) and in 936 participants randomly selected from the REGARDS cohort (comparison subcohort).
In multivariable-adjusted models, higher calcium and phosphorus concentrations, lower estimated glomerular filtration rate and higher urine albumin excretion were independently associated with higher FGF23. There was no statistically significant association of FGF23 with risk of all-cause stroke in Cox models adjusted for demographic factors and established stroke risk factors (hazard ratio comparing fourth with first quartile 1.19; 95% confidence interval, 0.78-1.82). In prespecified models stratified by stroke subtypes, there was a graded association of FGF23 with risk of cardioembolic stroke in fully adjusted models (quartile 1, reference; quartile 2 hazard ratio, 1.48; 95% confidence interval, 0.63-3.47; quartile 3 hazard ratio, 1.99; 95% confidence interval, 0.89-4.44; quartile 4 hazard ratio, 2.52; 95% confidence interval, 1.08-5.91). There were no statistically significant associations of FGF23 with other ischemic stroke subtypes or with hemorrhagic strokes.
Higher FGF23 concentrations were associated with higher risk of cardioembolic but not with other stroke subtypes in community-dwelling adults. Additional studies should delineate reasons for these findings.
成纤维细胞生长因子23(FGF23)是一种调节磷和维生素D代谢的激素。FGF23浓度升高与心血管疾病风险增加相关。FGF23与卒中结局的关联尚不清楚。
采用病例队列研究设计,在卒中地理和种族差异原因(REGARDS)研究中,我们研究了基线血浆FGF23浓度与卒中发病的关联,该研究队列包括年龄≥45岁的黑人和白人成年人。对615例发生卒中的参与者(病例)和从REGARDS队列中随机选取的936例参与者(对照亚队列)进行了FGF23检测。
在多变量调整模型中,较高的钙和磷浓度、较低的估计肾小球滤过率以及较高的尿白蛋白排泄与较高的FGF23独立相关。在调整了人口统计学因素和已确定的卒中危险因素的Cox模型中,FGF23与全因卒中风险无统计学显著关联(第四四分位数与第一四分位数相比的风险比为1.19;95%置信区间为0.78 - 1.82)。在按卒中亚型分层的预先设定模型中,在完全调整模型中FGF23与心源性栓塞性卒中风险存在分级关联(第一四分位数为参照;第二四分位数风险比为1.48;95%置信区间为0.63 - 3.47;第三四分位数风险比为1.99;95%置信区间为0.89 - 4.44;第四四分位数风险比为2.52;95%置信区间为1.08 - 5.91)。FGF23与其他缺血性卒中亚型或出血性卒中无统计学显著关联。
在社区居住的成年人中,较高的FGF23浓度与心源性栓塞性卒中风险较高相关,但与其他卒中亚型无关。进一步的研究应阐明这些发现的原因。